ViiV Announces Expanded Access of New Integrase Inhibitor…But Activists Are Concerned About Its Potential MisuseNelson Vergel
The dolutegravir expanded access program (EAP) has been designed to provide free access to Shionogi-ViiV Healthcare’s investigational integrase inhibitor, dolutegravir (DTG, S/GSK1349572) in an open-label protocol program to adults living with HIV who have documented raltegravir or elvitegravir resistance, who have limited treatment options, and who require DTG to construct a viable antiretroviral regimen for therapy. The dose is 50 mg twice a day for patients with multi drug resistance (the drug will also be eventually approved for once daily use for treatment naive patients)
But before you consider the use of this new drug, read the following warning: Activists Advise Caution About Access Program
Who can participate in the dolutegravir EAP (ING114916)?
How to apply for participation
What is dolutegravir?